Literature DB >> 33413564

ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma.

Qian Chen1, Xiao-Wei Zhou1, Ai-Jun Zhang2, Kang He3.   

Abstract

BACKGROUND: Alpha actinins (ACTNs) are major cytoskeletal proteins and exhibit many non-muscle functions. Emerging evidence have uncovered the regulatory role of ACTNs in tumorigenesis, however, the expression pattern, biological functions, and underlying mechanism of ACTN1 in hepatocellular carcinoma (HCC) remain largely unexplored.
METHODS: Immunohistochemical analysis of a HCC tissue microarray (n = 157) was performed to determine the expression pattern and prognostic value of ACTN1 in HCC. In vitro loss-of-function study in HCC cells were carried out to investigate ACTN1 knockdown on cell proliferation. In vivo subcutaneous xenograft model and intrahepatic transplantation model were generated to decipher the contribution of ACTN1 in the tumor growth of HCC. Gene set enrichment analysis, quantitative real-time PCR, Co-immunoprecipitation, immunofluorescence and western blotting were performed to identify the underlying molecular mechanism.
RESULTS: It was found that ACTN1 was significantly upregulated in HCC tissues and closely related to llpha-fetoprotein level, tumor thrombus, tumor size, TNM stage and patient prognoses. Knockdown of ACTN1 suppressed in vitro cell proliferation and in vivo tumor growth of HCC cells. Mechanistically, knockdown of ACTN1 increased Hippo signaling pathway activity and decreased Rho GTPases activities. Mechanistically, ACTN1 could competitively interact with MOB1 and decrease the phosphorylation of LATS1 and YAP. The growth-promoting effect induced by ACTN1 was significantly abrogated by pharmacological inhibition of YAP with verteporfin or super-TDU.
CONCLUSIONS: ACTN1 is highly expressed in HCC tissues and acts as a tumor promoter by suppressing Hippo signaling via physical interaction with MOB1. ACTN1 may serve as a potential prognostic marker and therapeutic target for HCC.

Entities:  

Keywords:  ACTN1; Hepatocellular carcinoma; Hippo signaling; Poor prognosis; Tumor growth

Year:  2021        PMID: 33413564      PMCID: PMC7791991          DOI: 10.1186/s13046-020-01821-6

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  9 in total

1.  S100A14 inhibits cell growth and epithelial-mesenchymal transition (EMT) in prostate cancer through FAT1-mediated Hippo signaling pathway.

Authors:  Shaoqin Jiang; Yaru Zhu; Zhenlin Chen; Zhangcheng Huang; Bingqiao Liu; Yue Xu; Zhihao Li; Zequn Lin; Mengqiang Li
Journal:  Hum Cell       Date:  2021-04-23       Impact factor: 4.174

2.  Construction of AP003469.4-miRNAs-mRNAs ceRNA network to reveal potential biomarkers for hepatocellular carcinoma.

Authors:  Tengyang Fan; Guojun Jiang; Rongshu Shi; Ronghua Yu; Xue Xiao; Di Ke
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

3.  α-Actinin1 promotes tumorigenesis and epithelial-mesenchymal transition of gastric cancer via the AKT/GSK3β/β-Catenin pathway.

Authors:  Siwen Zhang; Junfu Wang; Ting Chen; Jiancheng Wang; Ye Wang; Zhu Yu; Kun Zhao; Kaitian Zheng; Yeyang Chen; Zhen Wang; Bopei Li; Congjun Wang; Weijia Huang; Zhao Fu; Junqiang Chen
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity.

Authors:  Yan Fu; Hongfei Ci; Wei Du; Qiongzhu Dong; Huliang Jia
Journal:  Pharmaceutics       Date:  2022-01-25       Impact factor: 6.321

5.  Proteomic Signatures of Diffuse and Intestinal Subtypes of Gastric Cancer.

Authors:  Smrita Singh; Mohd Younis Bhat; Gajanan Sathe; Champaka Gopal; Jyoti Sharma; Anil K Madugundu; Neha S Joshi; Akhilesh Pandey
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

Review 6.  Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.

Authors:  Hyunjung Park; Hyerin Park; Jiyeon Baek; Hyuk Moon; Simon Weonsang Ro
Journal:  Biology (Basel)       Date:  2022-04-12

7.  A hybrid feature selection algorithm and its application in bioinformatics.

Authors:  Yangyang Wang; Xiaoguang Gao; Xinxin Ru; Pengzhan Sun; Jihan Wang
Journal:  PeerJ Comput Sci       Date:  2022-03-22

Review 8.  Advances in prognostic and therapeutic targets for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The hippo signaling pathway.

Authors:  Geofrey Mahiki Mranda; Zhi-Ping Xiang; Jun-Jian Liu; Tian Wei; Yinlu Ding
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

9.  From Bowen disease to cutaneous squamous cell carcinoma: eight markers were verified from transcriptomic and proteomic analyses.

Authors:  Tang Biao; He Cai-Feng; Lu Xiao-Hong; Chang Xiao-Li; Liu Wen-Bei; Wang Jun; Ci Chao; Yuan Tao
Journal:  J Transl Med       Date:  2022-09-09       Impact factor: 8.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.